Baker BROS. Advisors LP Sells 5,845,706 Shares of DBV Technologies S.A. (NASDAQ:DBVT)

Baker BROS. Advisors LP lowered its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,461,425 shares of the company's stock after selling 5,845,706 shares during the quarter. Baker BROS. Advisors LP owned approximately 7.10% of DBV Technologies worth $4,516,000 as of its most recent SEC filing.

Separately, Boxer Capital Management LLC acquired a new position in DBV Technologies in the fourth quarter valued at $154,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Stock Performance

Shares of DBVT remained flat at $9.84 during trading hours on Friday. 56,037 shares of the company were exchanged, compared to its average volume of 185,117. The stock has a market cap of $269.52 million, a P/E ratio of -2.19 and a beta of -0.66. The stock has a 50 day moving average price of $6.80 and a two-hundred day moving average price of $4.82. DBV Technologies S.A. has a one year low of $2.20 and a one year high of $10.12.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, sell-side analysts expect that DBV Technologies S.A. will post -7.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DBVT shares. StockNews.com upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday. JMP Securities boosted their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 1st. Finally, HC Wainwright raised their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.